These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4362229)

  • 21. Intracerebroventricularly infused [D-Arg1]angiotensin III, is superior to [D-Asp1]angiotensin II, as a pressor agent in rats.
    Wright JW; Roberts KA; Cook VI; Murray CE; Sardinia MF; Harding JW
    Brain Res; 1990 Apr; 514(1):5-10. PubMed ID: 2357530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of aminopeptidase inhibitors on angiotensin-induced pressor responses.
    Sullivan MJ; Harding JW; Wright JW
    Brain Res; 1988 Jul; 456(2):249-53. PubMed ID: 3208081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of angiotensin II antagonists containing sarcosine in position 7.
    Moore GJ; Oudeman EM; Ko D; Nystrom DM
    J Med Chem; 1979 Sep; 22(9):1147-9. PubMed ID: 490564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzymatic degradation and electrophoresis of human angiotensin I.
    Arakawa K; Minohara A; Yamada J; Nakamura M
    Biochim Biophys Acta; 1968 Sep; 168(1):106-12. PubMed ID: 4300938
    [No Abstract]   [Full Text] [Related]  

  • 25. The synthesis of six C-peptide sequences of porcine proinsulin for immunological studies.
    Naithani VK
    Hoppe Seylers Z Physiol Chem; 1973 Jan; 354(1):67-74. PubMed ID: 4807789
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of endogenous bradykinin on acute blood pressure response to vasopressors in normotensive rats assessed with a bradykinin antagonist.
    Aubert JF; Waeber B; Nussberger J; Vavrek R; Stewart JM; Brunner HR
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):51-5. PubMed ID: 2450256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid-phase synthesis of (6-arginine)-, (4-histidine, 6-tyrosine)-, and (8-isoleucine)angiotensins II.
    Khosla MC; Kumar S; Smeby RR; Bumpus FM
    J Med Chem; 1972 Jun; 15(6):627-9. PubMed ID: 4337901
    [No Abstract]   [Full Text] [Related]  

  • 28. Isolation and characterization of a new bradykinin potentiating octapeptide from gamma-casein.
    Lebrun I; Lebrun FL; Henriques OB; Carmona AK; Juliano L; Camargo AC
    Can J Physiol Pharmacol; 1995 Jan; 73(1):85-91. PubMed ID: 7600458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alkylating analogs of peptide hormones. 2. Synthesis and properties of p-(N,N-bis(2-chloroethyl)amino)phenylbutyryl derivatives of angiotensin II.
    Paiva TB; Paiva AC; Freer RJ; Stewart JM
    J Med Chem; 1972 Jan; 15(1):6-8. PubMed ID: 4331919
    [No Abstract]   [Full Text] [Related]  

  • 30. Possible involvement of aminopeptidase A in hypertension in spontaneously hypertensive rats (SHRs) and change of refractoriness in response to angiotensin II in pregnant SHRs.
    Nakashima Y; Ohno Y; Itakura A; Takeuchi M; Murata Y; Kuno N; Mizutani S
    J Hypertens; 2002 Nov; 20(11):2233-8. PubMed ID: 12409962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pressor substances in the posthemodialysis dialysates of patients with toxemia of pregnancy.
    Vorne MS; Järvinen PA; Järvi J; Ylöstalo PR; Kärki NT
    Am J Obstet Gynecol; 1974 Jul; 119(5):610-6. PubMed ID: 4365676
    [No Abstract]   [Full Text] [Related]  

  • 32. Synthesis and biological activity of angiotensin II analogues containing a Val-His replacement, Val psi[CH(CONH2)NH]His.
    Mohan R; Chou YL; Bihovsky R; Lumma WC; Erhardt PW; Shaw KJ
    J Med Chem; 1991 Aug; 34(8):2402-10. PubMed ID: 1875337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-like and antagonistic activities of N-terminal modified (8-leucine)angiotensin II peptides.
    Paiva TB; Goissis G; Juliano L; Miyamoto ME; Paiva AC
    J Med Chem; 1974 Feb; 17(2):239-41. PubMed ID: 4358432
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostaglandin release from vasculature by angiotensin II: dissociation from lipolysis.
    Needleman P; Marshall GR; Douglas JR
    Eur J Pharmacol; 1973 Sep; 23(3):316-9. PubMed ID: 4355731
    [No Abstract]   [Full Text] [Related]  

  • 35. Reputed rat scotophobin prepared by a solid-phase procedure shown invalid by comparison with a product derived from a classical synthesis on the basis of physical and biological properties.
    Guttman HN; Weinstein B; Bartschot RM; Tam PS
    Experientia; 1975 Mar; 31(3):285-8. PubMed ID: 1167829
    [No Abstract]   [Full Text] [Related]  

  • 36. Formation of vasoactive substances by trypsin--effect of pH differences on the generation.
    Ikeda M; Sakai T; Yuki M; Geji T; Arakawa K
    Jpn Circ J; 1977 Aug; 41(8):871-2. PubMed ID: 20522
    [No Abstract]   [Full Text] [Related]  

  • 37. The solid phase syntheses of 5-isoleucine-angiotensin I and 5-isoleucine (10-14C(U),-leucine)-angiotensin I.
    Thampi NS; Schoellmann G; Hurst MW; Huggins CG
    Life Sci; 1968 Jun; 7(12):641-5. PubMed ID: 4299705
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthesis of [5-isoleucine, 8-alanine]-angiotensin II by the solution method synthesis and the solid-phase method synthesis.
    Park WK; Smeby RR; Bumpus FM
    Biochemistry; 1967 Nov; 6(11):3458-64. PubMed ID: 4294489
    [No Abstract]   [Full Text] [Related]  

  • 39. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro.
    Haugen EN; Croatt AJ; Nath KA
    Kidney Int; 2000 Jul; 58(1):144-52. PubMed ID: 10886559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorescamine as a terminating agent in solid phase peptide synthesis.
    Felix AM; Jimenez H; Vergona R; Cohen MR
    Int J Pept Protein Res; 1975; 7(1):11-22. PubMed ID: 1120631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.